Nuvation Bio/$NUVB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Ticker
$NUVB
Sector
Primary listing
NYSE
Employees
278
Headquarters
Website
Nuvation Bio Metrics
BasicAdvanced
$1.1B
-
-$0.63
1.35
-
Price and volume
Market cap
$1.1B
Beta
1.35
52-week high
$4.09
52-week low
$1.54
Average daily volume
5.7M
Financial strength
Current ratio
9.392
Quick ratio
9.259
Long term debt to equity
13.508
Total debt to equity
15.49
Interest coverage (TTM)
293.03%
Profitability
EBITDA (TTM)
201.481
Gross margin (TTM)
27.54%
Net profit margin (TTM)
-1,413.43%
Operating margin (TTM)
1,396.27%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
20.17%
Return on equity (TTM)
-44.84%
Valuation
Price to revenue (TTM)
74.627
Price to book
3.05
Price to tangible book (TTM)
3.15
Price to free cash flow (TTM)
-6.355
Free cash flow yield (TTM)
-15.74%
Free cash flow per share (TTM)
-0.522
Growth
Revenue change (TTM)
900.35%
Earnings per share change (TTM)
-72.24%
3-year earnings per share growth (CAGR)
8.80%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Bulls say / Bears say
FDA approval of Ibtrozi grants access to the U.S. market for taletrectinib, providing Nuvation with its first marketed product and a defined opportunity to generate revenue in the near term. (Reuters)
RBC Capital Markets projects Ibtrozi could bring in as much as $640 million annually at its peak by 2034, suggesting significant long-term growth potential if sales meet expectations. (Reuters)
Taletrectinib produced strong response rates and lasting benefits in two mid-stage clinical studies, strengthening its position versus other ROS1 inhibitors and boosting investor belief in its effectiveness. (Reuters)
Nuvation’s stock fell 17.4% following Ibtrozi’s approval, signaling investor doubts about the drug’s launch execution and how well it will be received in the market. (Reuters)
The ROS1+ NSCLC indication only covers about 3,000 new U.S. cases per year, meaning Ibtrozi’s peak sales opportunity may be limited to a small patient population. (Reuters)
Ibtrozi will compete against three already marketed ROS1 inhibitors—Augtyro, Xalkori and Rozlytrek—in a niche ROS1+ NSCLC field, which could limit pricing power and market share. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Nuvation Bio News
AllArticlesVideos
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
Business Wire4 days ago
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $1.1B as of September 11, 2025.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of September 11, 2025.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.